Regavirumab

Regavirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	cytomegalovirus glycoprotein B
Clinical data
ATC code	none
Identifiers
CAS Number	153101-26-9^N
ChemSpider	none
^NY (what is this?) (verify)

Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.^[1]

References

↑ Arizono, H; Sugano, T; Kaida, S; Shibusawa, K; Karasawa, Y; Esumi, Y; Kondo, S; Kiyoki, M (1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung. 44 (7): 909–13. PMID 7945531.

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.